Your browser doesn't support javascript.
loading
Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group.
Lafarge, Antoine; Joseph, Adrien; Pagnoux, Christian; Puéchal, Xavier; Cohen, Pascal; Samson, Maxime; Hamidou, Mohamed; Karras, Alexandre; Quemeneur, Thomas; Ribi, Camillo; Groh, Matthieu; Mouthon, Luc; Guillevin, Loïc; Terrier, Benjamin.
Afiliação
  • Lafarge A; Department of Internal Medicine.
  • Joseph A; National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital.
  • Pagnoux C; INSERM, U1138, Paris, France.
  • Puéchal X; Department of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada.
  • Cohen P; Department of Internal Medicine.
  • Samson M; National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital.
  • Hamidou M; Department of Internal Medicine.
  • Karras A; National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital.
  • Quemeneur T; Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, Dijon.
  • Ribi C; Department of Internal Medicine, Hôtel Dieu, Nantes.
  • Groh M; Department of Nephrology, Hôpital Européen Georges Pompidou, Paris.
  • Mouthon L; Department of Internal Medicine, Hôpital de Valenciennes, Valenciennes, France.
  • Guillevin L; Department of Immunology, CHUV, Lausanne, Switzerland.
  • Terrier B; Department of Internal Medicine.
Rheumatology (Oxford) ; 59(9): 2250-2257, 2020 09 01.
Article em En | MEDLINE | ID: mdl-31782786
ABSTRACT

OBJECTIVES:

Infections remain a major cause of morbidity and mortality in systemic necrotizing vasculitides (SNV). We aimed to identify factors predicting severe infections (SI) in SNV.

METHODS:

Data from five randomized controlled trials (RCTs) enrolling 733 patients were pooled. The primary end point was the occurrence of SI, defined by the need of a hospitalization and/or intravenous anti-infectious treatment and/or leading to death.

RESULTS:

After a median follow-up of 5.2 (interquartile range 3-9.7) years, 148 (20.2%) patients experienced 189 SI, and 98 (66.2%) presented their first SI within the first 2 years. Median interval from inclusion to SI was 14.9 (4.3-51.7) months. Age ≥65 years (hazard ratio (HR) 1.49 [1.07-2.07]; P=0.019), pulmonary involvement (HR 1.82 [1.26-2.62]; P=0.001) and Five Factor Score ≥1 (HR 1.21 [1.03-1.43]; P=0.019) were independent predictive factors of SI. Regarding induction therapy, the occurrence of SI was associated with the combination of GCs and CYC (HR 1.51 [1.03-2.22]; P = 0.036), while patients receiving only GCs were less likely to present SI (HR 0.69 [0.44-1.07]; P = 0.096). Finally, occurrence of SI had a significant negative impact on survival (P<0.001).

CONCLUSION:

SI in SNV are frequent and impact mortality. Age, pulmonary involvement and Five Factor Score are baseline independent predictors of SI. No therapeutic regimen was significantly associated with SI but patients receiving glucocorticoids and CYC as induction tended to have more SI.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Poliarterite Nodosa / Índice de Gravidade de Doença / Antirreumáticos / Imunossupressores / Infecções Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Poliarterite Nodosa / Índice de Gravidade de Doença / Antirreumáticos / Imunossupressores / Infecções Idioma: En Ano de publicação: 2020 Tipo de documento: Article